Edition:
United States

Baxter International Inc (BAX.N)

BAX.N on New York Stock Exchange

62.67USD
21 Jul 2017
Change (% chg)

$-0.37 (-0.59%)
Prev Close
$63.04
Open
$62.89
Day's High
$63.09
Day's Low
$62.60
Volume
759,608
Avg. Vol
791,478
52-wk High
$63.09
52-wk Low
$43.14

Latest Key Developments (Source: Significant Developments)

Baxter debuts enteral nutrition ENFit syringe and accessory line in clinical nutrition week 2017
Thursday, 16 Feb 2017 08:30am EST 

Baxter International Inc - : Baxter debuts enteral nutrition ENFit syringe and accessory line during clinical nutrition week 2017 . Expansion of nutrition care portfolio to include new enteral ENFit syringe, accessory line for patients requiring tube feeding .Plans to launch its enteral ENFit syringes, accessories in US , Canada, select European countries, Australia, New Zealand in 2017.  Full Article

Baxter International reports Q4 earnings per share of $0.44
Wednesday, 1 Feb 2017 07:30am EST 

Baxter International Inc : Baxter reports 2016 fourth-quarter and full-year results . Sees Q1 2017 earnings per share $0.50 to $0.52 from continuing operations excluding items . Baxter International Inc says fourth-quarter revenue of $2.6 billion increased 2 percent on a reported and constant currency basis . Baxter International Inc says fourth-quarter GAAP earnings per share of $0.44; adjusted earnings per share of $0.57 increased 33 percent . Baxter International - worldwide sales totaled $2.6 billion in Q4, increase of 2 percent on reported and constant currency basis versus prior-year period . Baxter -renal sales totaled $1 billion in Q4, representing a 3 percent increase on a reported basis, and a 5 percent increase on a constant currency basis . Baxter International Inc sees Q1 GAAP earnings per share $0.39 - $0.42 . Baxter International - for FY 2017, expects sales to be comparable to prior-year period on reported basis, increase about 2 percent on constant currency basis . Baxter International Inc - for Q1, company expects sales growth of approximately 2 to 3 percent on a reported basis . Baxter International Inc sees Q1 adjusted earnings per share $0.50 - $0.52 . Baxter International Inc - expects earnings from continuing operations, before special items, of $2.10 to $2.18 per diluted share for full-year 2017 . Says expects 2017 underlying constant currency sales growth of approximately 4 percent.  Full Article

Baxter Q3 adj earnings per share $0.56 from continuing operations excluding items
Tuesday, 25 Oct 2016 07:00am EDT 

Baxter International Inc : Baxter reports third quarter 2016 results and increases financial outlook for full-year 2016 . Sees Q4 2016 earnings per share $0.49 to $0.52 from continuing operations excluding items . Q3 GAAP earnings per share $0.23 from continuing operations . Q3 sales $2.6 billion versus i/b/e/s view $2.55 billion . Q3 earnings per share view $0.45 -- Thomson Reuters I/B/E/S . Raises FY 2016 earnings per share view to $1.88 to $1.91 from continuing operations excluding items . Q3 adjusted earnings per share $0.56 from continuing operations excluding items . Sees Q4 sales up about 2 percent . Baxter international inc - raising its financial outlook for full-year 2016 including sales growth of approximately 2 percent on a reported basis . Fy2016 earnings per share view $1.72, revenue view $10.15 billion -- Thomson Reuters I/B/E/S . Sees earnings from continuing operations, before special items, of $1.88 to $1.91 per diluted share for full year . Fy2016 earnings per share view $1.72 -- Thomson Reuters I/B/E/S . Baxter International Inc - on an adjusted basis Baxter's Q3 income from continuing operations totaled $0.56 per diluted share .Baxter International Inc - for Q4, company expects sales growth of approximately 2 percent on both a reported and constant currency basis.  Full Article

Sunshine Heart buys Baxter's Aquadex product line
Monday, 8 Aug 2016 05:30am EDT 

Sunshine Heart Inc: Sunshine Heart announces strategic acquisition of Aquadex product line from Baxter and a new credit facility with Silicon Valley Bank . Under terms of agreement, Baxter received $4.0 million in cash and 1.0 million shares of Sunshine Heart common stock . Entered into a new $5.0 million facility to finance future working capital needs . Company repaid all amounts outstanding under its existing debt facility with Silicon Valley Bank ."Expect product line to be accretive in first year".  Full Article

Baxter Q2 earnings $2.19/shr from cont ops
Tuesday, 26 Jul 2016 07:00am EDT 

Baxter Reports Second Quarter 2016 Results And Raises Financial Outlook For Full : Baxter reports second quarter 2016 results and raises financial outlook for full-year 2016 . For full-year 2016, baxter now expects sales growth of 3 percent to 4 percent on a constant currency basis . Year 2016 . Sees fy 2016 earnings per share $1.69 to $1.74 from continuing operations excluding items . Sees q3 2016 earnings per share $0.43 to $0.45 from continuing operations excluding items . Q2 gaap earnings per share $2.19 from continuing operations . Q2 sales $2.6 billion versus i/b/e/s view $2.52 billion . Q2 adjusted earnings per share $0.46 from continuing operations excluding items . Q2 earnings per share view $0.40 -- Thomson Reuters I/B/E/S . For full-year 2016, baxter now expects reported sales growth of 1 percent to 2 percent . Fy2016 earnings per share view $1.64, revenue view $10.09 billion -- Thomson Reuters I/B/E/S .Q3 earnings per share view $0.42, revenue view $2.53 billion -- Thomson Reuters I/B/E/S.  Full Article

EU Medicines Agency recommends approval of two new cancer drugs
Friday, 22 Jul 2016 07:21am EDT 

EU Medicines Agency : EU medicines agency recommendations for july 2016 . Recommends approval of Exelixis Inc’S cabozantinib to treat advanced renal cell carcinoma .Recommends Approval Of Baxter International Inc’S Irinotecan to treat pancreatic cancer.  Full Article

Baxter International sets quarterly dividend of $0.13 per share
Tuesday, 19 Jul 2016 09:00am EDT 

Baxter International Inc :Sets quarterly dividend of $0.13 per share.  Full Article

Baxter says Delaware court validates amendment to declassify company's board
Thursday, 23 Jun 2016 05:21pm EDT 

Baxter International Inc : Court of Chancery of State of Delaware validated charter amendment to declassify company's board of directors .Charter amendment will become effective on august 1, 2016.  Full Article

Baxter expects to generate free cash flow of about $1.75 bln in 2020
Monday, 9 May 2016 04:05pm EDT 

Baxter International Inc : Company provides financial outlook for 2018 and 2020 . Expects to grow sales 3 to 4 percent on a compounded annual basis at constant currency rates from 2016 through 2018 . Expects a 2018 adjusted operating margin of 14 to 15 percent and 2018 adjusted diluted earnings of $2.10 to $2.25 per share . Also expects free cash flow (operating cash flow less capital expenditures) of approximately $1.0 billion in 2018 . Expects sales to grow approximately 4 percent on a compounded annual basis at constant currency rates from 2016 to 2020 . Anticipates an adjusted operating margin of 17 to 18 percent and adjusted diluted earnings of $2.75 to $3.00 per share in 2020 .Expects to generate free cash flow of approximately $1.75 billion in 2020.  Full Article

Baxter International Inc raises quarterly dividend
Tuesday, 3 May 2016 08:30am EDT 

Baxter International Inc:Board of Directors has declared a 13 percent increase in the company's quarterly dividend rate, from the previous rate of $0.115 per Baxter common share to $0.13 per share.Dividend is payable on July 1, 2016 to stockholders of record as of June 3, 2016.  Full Article

U.S. FTC approves Baxter's acquisition of Claris business with condition

WASHINGTON Baxter International Inc and Claris Lifesciences Ltd have agreed to divest two types of pharmaceutical products to settle U.S. Federal Trade Commission charges that Baxter's proposed acquisition of Claris’ injectable drugs business is anticompetitive, the agency said on Thursday.